JAGSNPHARM
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) Stock Analysis
Jagsonpal Pharmaceuticals Limited makes pharmaceutical formulations in women's health and primary care segments. It sells branded generics through medical representatives and chemists. The company has a focused therapeutic portfolio. It is a listed pharma firm.
Healthcare › Drug Manufacturers - Specialty & Generic
₹225.60
-2.65% 1W | +6.60% 52W
Market Cap
1.5k CR
P/E Ratio
33.6
52W High
₹264.5
52W Low
₹155
Div. Yield
1.08%
Beta
-0.3
50 DMA
₹234.4
200 DMA
₹205.7
Profit Margin
15.5%
Inst. Own.
2.6%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 |
| Expenses | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 | 57 | 53 | 65 |
| Operating Profit | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 | 16 | 11 | 17 |
| OPM % | 14% | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% | 22% | 22% | 17% | 21% |
| Other Income | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 | 1 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 |
| Tax % | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 |
| EPS in Rs | 1.14 | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 | 1.31 | 2.00 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 287 | 294 |
| Expenses | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 229 | 233 |
| Operating Profit | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 58 | 61 |
| OPM % | 6% | 8% | 4.0% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% | 21% |
| Other Income | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 10 | 10 |
| Interest | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 | 9 |
| Profit before tax | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 58 | 61 |
| Tax % | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | 25% | |
| Net Profit | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 43 | 45 |
| EPS in Rs | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 6.43 | 6.84 |
| Dividend Payout % | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% | 62% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 9.0% | 7.0% |
| Profit CAGR | 16.0% | 21.0% | 30.0% |
Shareholding Pattern
Promoters67.65%
FIIs2.17%
DIIs0.05%
Public30.12%
Promoters67.54%
FIIs2.12%
DIIs0.08%
Public30.25%
Promoters67.39%
FIIs2.12%
DIIs0.15%
Public30.34%
Promoters67.89%
FIIs2.44%
DIIs0.22%
Public29.44%
Promoters69.06%
FIIs2.30%
DIIs0.62%
Public28.04%
Promoters68.72%
FIIs0.10%
DIIs0.82%
Public30.34%
Promoters68.09%
FIIs0.73%
DIIs0.84%
Public30.33%
Promoters67.77%
FIIs2.10%
Public30.11%
Promoters67.89%
FIIs2.44%
DIIs0.22%
Public29.44%
Promoters69.06%
FIIs2.30%
DIIs0.62%
Public28.04%
JAGSNPHARM
Holdings Analysis
Key strengths & risk signals
72
Overall
68
Fundamental
77
Technical
Risks (3)
RECOVERY MODE! Current price (225.6) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.6% (1 week), 4.2% (1 month), 3.1% (3 months).
POSITIVE YEAR! Stock gained 6.6% in the last year.
Strengths (4)
FAIRLY VALUED! PEG of 1.94 indicates reasonable valuation.
BULLISH TREND! 50-day average (234.4) is above 200-day average (205.7) - positive signal.
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 1,058,796 vs down days: 110,732. Ratio: 9.56x
LOW VOLATILITY! Beta of -0.30 - stable stock, less market risk.
Fundamental & Technical Analysis
72Overall
68Fundamental
77Technical
Fundamental Breakdown
Growth Quality
21/30
Revenue CAGR: 6.7% (MODERATE, 8/15). Profit CAGR: 17.3% (VERY GOOD, 13/15).
Profit Margin
6/10
GOOD EFFICIENCY! 15.5% profit margin - above average profitability.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.94 indicates reasonable valuation.
Dividend Yield
5/10
LOW DIVIDEND! 1.08% yield - minimal income contribution.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 30.07% public ownership - moderate retail influence.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (234.4) is above 200-day average (205.7) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (225.6) above 200-day but below 50-day.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
4/10
POSITIVE YEAR! Stock gained 6.6% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 1,058,796 vs down days: 110,732. Ratio: 9.56x
RSI
3/5
NEUTRAL! RSI at 42.3 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 64.5% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.6% (1 week), 4.2% (1 month), 3.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of -0.30 - stable stock, less market risk.
JAGSNPHARM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-04 | Concall PDF | |
| Q4FY262026-05-04 | Concall PDF | |
| Q2FY262026-01-27 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JAGSNPHARM | ₹225.60 | 33.6 | 15.5% | 6.7% | 17.3% | +6.6% | 72 | BOUNCE FROM SUPPORT | +22.2% | +50.0% | +8.7% | +28.0% |
| FERMENTA | ₹517.50 | 25 | 11.7% | 14.5% | – | +24.5% | 65 | CONSOLIDATING DOWN | -55.5% | -49.5% | -10.6% | +0.2% |
| AHCL | ₹28.10 | 41.3 | 14.0% | 15.1% | 69.8% | +107.2% | 81 | BREAKOUT | +91.4% | -36.2% | +163.1% | +72.1% |
| AMRUTANJAN | ₹508.90 | 27.3 | 10.6% | 9.9% | 13.3% | -26.2% | 54 | APPROACHING RESISTANCE | -47.0% | -72.8% | +9.6% | -31.2% |
| HESTERBIO | ₹2,058.70 | 12.8 | 41.6% | 7.7% | 27.8% | +24.4% | 76 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| LINCOLN | ₹558.30 | 11.6 | 13.9% | 9.5% | 6.4% | +6.6% | 57 | BREAKDOWN | +30.7% | +212.1% | +15.1% | -5.3% |
| SIGACHI | ₹28.50 | 42.6 | 5.4% | 16.5% | – | -24.4% | 56 | BREAKDOWN | -106.8% | -11.7% | -5.4% | -0.5% |
| BAJAJHCARE | ₹320.00 | 46.2 | 2.8% | -1.8% | -28.4% | -32.8% | 44 | BOUNCE FROM SUPPORT | +16.1% | -159.8% | +11.3% | +8.2% |
Data from TradeAlone · Updated daily
JAGSNPHARM News
Jagsonpal Pharmaceuticals Limited Acquires Wellness Portfolio of Group Pharmaceuticals2026-09-23Jagsonpal Pharmaceuticals Limited (jagsnpharm) Q1 FY27 Results: Revenue Up 9%, PAT Up 22%2026-07-29Jagsonpal Pharmaceuticals Limited (jagsnpharm) to Acquire 85% Stake in Aequitas Healthcare2026-06-29Jagsonpal Pharmaceuticals Limited (jagsnpharm) Appoints Industry Veteran Anil Kumar Matai as Independent Director2026-06-25
